Custom Built Biology for Patients

November 2022

Molecular Partners AG, Switzerland (SIX: MOLN, NASDAQ: MOLN)

1

Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constituteforward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, including expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinicaltrials, expectations regarding interactions with regulatory authorities, the potential therapeutic and clinicalbenefits of Molecular Partners' product candidates, the selection and development of future antiviral or other programs, or other potential business development opportunities for product candidates, and Molecular Partners' expected expenses and cash utilization for 2022 and that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into 2026. These statements may be identified by words such as "anticipate", "believe", "could", "expect", "intend", "may", "plan", "potential", "will", "would" and similar expressions, although not al l forward-looking statements may contain these identifying words, and are based on Molecular Partners' current beliefs and expectations. Thesestatements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Someof the key factors that could cause actual results to differ from our expectations include Molecular Partners' or its collaborators' plans to develop and potentially

commercializeits product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinicalstudies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinicaltrials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achievemarket acceptance of Molecular Partners' product candidates; the potential impact of the COVID-19pandemic or other geopolitical events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; the adequacy of Molecular Partners' cash resources and our anticipated cash utilization; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Annual Report on Form 20-F for the year

ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 15, 2022, and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at http://www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this presentation, and except to the extent required by law, Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

2

Molecular Partners Highlights

Science Highlights:

MP0533: Tri-specificT-cell engager for AML

  • On track to reach clinical initiation by end 2022
  • Oral presentation at ASH 2022

Abicipar:

  • FDA supports single safety trial for approval
  • Reviewing path forward outside MP

MP0317: Bi-specific CD40 local agonist

  • In Phase 1 - enrollment ongoing at 3 mg/kg dose level
  • Positive initial data presented at SITC

DARPin-radioligand therapies:

  • Deal with Novartis on 2 targets: CHF 18.6 million received, to date
  • Internal research - ongoing with initial targets nominated in H1 23

Operational Highlights:

  • Reported cash and equivalents as of September 30, 2022: CHF ~267 million
  • Consistent, disciplined spend rate
    • Runway into 2026

3

Strategy: Highly Differentiated Programs, True Patient Value

PATIENT VALUE

DARPin

ADVANTAGE

BIOLOGY

PARTNERING

We aim to drive true patient value with an early clinical read-out by directly changing the course of disease

We leverage the advantages of DARPins to provide unique solutions to patients with high medical need, no satisfactory solutions and well-defined disease biology

We target biological hypothesis that can be tested in relevant preclinical models with translatable value - focus on oncology and virology

We share an open mindset and collaborate with world leading companies, scientists and clinicians from ideation to approval

4

DARPins: The Core of our Drug Engine

DARPins are binding proteins derived from natural ankyrin repeat proteins

DARPin

Target protein

DARPin KEY PROPERTIES

DARPin ADVANTAGE

Small size

Deep tissue penetration

(15 kDa)

High molar concentration

Rigid protein

Ultra-high binding affinity

scaffold

and selectivity

Simple & robust

Turn-key multispecifics

architecture

Easy coupling of payloads

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Molecular Partners AG published this content on 15 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2022 20:38:00 UTC.